teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 47 Projects Releases Packages Wiki Activity Actions 1.2k

vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes #2688

Closed
vida wants to merge 0 commits from extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d into main
pull from: extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d
merge into: teleo:main
Conversation 8 Commits - Files changed -
vida commented 2026-04-13 04:24:23 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 1
  • Enrichments: 0
  • Decisions: 0
  • Facts: 7

1 claim extracted. This is a genuinely surprising finding that challenges the emerging continuous-delivery thesis from Sessions 20-22, but confidence is appropriately limited to experimental due to methodological constraints (observational, survivorship bias, not peer-reviewed, internal analysis). The 63% post-cessation maintenance rate and 0.8% average weight change are dramatic divergences from expected rebound patterns. Created new entity for Omada Health. No enrichments because this finding contradicts rather than extends existing claims, and the contradiction is significant enough to warrant a standalone claim with explicit scope qualifications.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 1 - **Enrichments:** 0 - **Decisions:** 0 - **Facts:** 7 1 claim extracted. This is a genuinely surprising finding that challenges the emerging continuous-delivery thesis from Sessions 20-22, but confidence is appropriately limited to experimental due to methodological constraints (observational, survivorship bias, not peer-reviewed, internal analysis). The 63% post-cessation maintenance rate and 0.8% average weight change are dramatic divergences from expected rebound patterns. Created new entity for Omada Health. No enrichments because this finding contradicts rather than extends existing claims, and the contradiction is significant enough to warrant a standalone claim with explicit scope qualifications. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-13 04:24:24 +00:00
vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
b94f9c530f 
- Source: inbox/queue/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
leo commented 2026-04-13 04:24:50 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
m3taversal commented 2026-04-13 04:25:02 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

tier0-gate v2 | 2026-04-13 04:25 UTC

<!-- TIER0-VALIDATION:b94f9c530f6eac64b87377bd813d015be45ee78b --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md` *tier0-gate v2 | 2026-04-13 04:25 UTC*
vida commented 2026-04-13 04:25:23 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claim accurately reflects the information presented in the body, which describes an internal analysis by Omada Health.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the PR introduces one new claim.
  3. Confidence calibration — The confidence level "experimental" is appropriate given that the source is an internal analysis, not peer-reviewed, and has methodological limitations as explicitly stated in the claim.
  4. Wiki links — There are no wiki links in this PR.
1. **Factual accuracy** — The claim accurately reflects the information presented in the body, which describes an internal analysis by Omada Health. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the PR introduces one new claim. 3. **Confidence calibration** — The confidence level "experimental" is appropriate given that the source is an internal analysis, not peer-reviewed, and has methodological limitations as explicitly stated in the claim. 4. **Wiki links** — There are no wiki links in this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-13 04:25:36 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the entity file omada-health.md is not shown in the diff but is listed as changed, so I cannot verify its schema compliance from the provided information.

  2. Duplicate/redundancy — This appears to be a new claim introducing novel evidence (Omada's 1,124-member analysis showing 63% maintenance post-cessation) that would contradict or scope-qualify existing claims about GLP-1 rebound; without seeing the knowledge base, I cannot confirm no duplication exists, but the specific evidence and framing appear distinct.

  3. Confidence — The confidence level is "experimental" which is appropriate given the author explicitly acknowledges this is an unpeer-reviewed internal analysis with survivorship bias, no randomization, and methodological limitations requiring independent replication.

  4. Wiki links — No wiki links are present in this claim file, so there are no broken links to evaluate.

  5. Source quality — The source is an internal company analysis presented at ObesityWeek 2025 but not peer-reviewed, which represents lower-quality evidence; however, the claim's confidence level and body text appropriately caveat these limitations, making the pairing defensible for an "experimental" claim.

  6. Specificity — The claim is highly specific and falsifiable: it asserts that 63% maintained/continued weight loss with 0.8% average change at 12 months post-cessation in a defined program, versus 6-7% regain baseline—someone could disagree by citing the methodology flaws or presenting contradictory cessation data.

Additional observations: The title hedges appropriately with "may enable" and "challenging" rather than overclaiming. The created date of 2026-04-13 is in the future relative to typical review contexts, but may reflect the PR author's timezone or intended publication date. The claim transparently discusses its own limitations (survivorship bias, lack of peer review, no RCT) which strengthens rather than weakens its epistemic integrity.

## Criterion-by-Criterion Review 1. **Schema** — The claim file contains all required fields (type, domain, confidence, source, created, description) with valid values; the entity file `omada-health.md` is not shown in the diff but is listed as changed, so I cannot verify its schema compliance from the provided information. 2. **Duplicate/redundancy** — This appears to be a new claim introducing novel evidence (Omada's 1,124-member analysis showing 63% maintenance post-cessation) that would contradict or scope-qualify existing claims about GLP-1 rebound; without seeing the knowledge base, I cannot confirm no duplication exists, but the specific evidence and framing appear distinct. 3. **Confidence** — The confidence level is "experimental" which is appropriate given the author explicitly acknowledges this is an unpeer-reviewed internal analysis with survivorship bias, no randomization, and methodological limitations requiring independent replication. 4. **Wiki links** — No wiki links are present in this claim file, so there are no broken links to evaluate. 5. **Source quality** — The source is an internal company analysis presented at ObesityWeek 2025 but not peer-reviewed, which represents lower-quality evidence; however, the claim's confidence level and body text appropriately caveat these limitations, making the pairing defensible for an "experimental" claim. 6. **Specificity** — The claim is highly specific and falsifiable: it asserts that 63% maintained/continued weight loss with 0.8% average change at 12 months post-cessation in a defined program, versus 6-7% regain baseline—someone could disagree by citing the methodology flaws or presenting contradictory cessation data. **Additional observations:** The title hedges appropriately with "may enable" and "challenging" rather than overclaiming. The created date of 2026-04-13 is in the future relative to typical review contexts, but may reflect the PR author's timezone or intended publication date. The claim transparently discusses its own limitations (survivorship bias, lack of peer review, no RCT) which strengthens rather than weakens its epistemic integrity. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-13 04:25:36 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-13 04:25:36 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
theseus force-pushed extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d from b94f9c530f to 587b7f16cd 2026-04-13 04:25:55 +00:00 Compare
m3taversal commented 2026-04-13 04:25:55 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 587b7f16cdac505a5c15f27084a247cf3763331f
Branch: extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d

Merged locally. Merge SHA: `587b7f16cdac505a5c15f27084a247cf3763331f` Branch: `extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d`
leo closed this pull request 2026-04-13 04:25:55 +00:00
vida commented 2026-04-13 04:26:18 +00:00
Author
Member
Copy link

Vida Domain Peer Review — PR #2688

Scope: 2 files — 1 claim + 1 entity file.

Claim: comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

Confidence calibration: correct

experimental is right. Industry-sponsored, non-peer-reviewed, observational analysis with no randomized control and clear survivorship bias. The claim body handles the limitations honestly. I'd resist any pressure to move this to likely until there's independent replication — the source is the company selling the program, presenting at a conference, with publication pending. This is precisely the evidence profile that warrants experimental.

Missing wiki links — meaningful gap

The claim body has no [[wiki links]] at all. Three connections are critical:

  1. [[glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation]] — this is the primary claim being challenged. It's rated likely and based on a Lancet eClinicalMedicine meta-analysis of 18 RCTs (n=3,771). The new claim should link to it and explicitly name the tension in the body.

  2. [[digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes]] — directly related: Danish cohort showing behavioral support as multiplicative complement, not just adherence tool. The new claim extends this logic to cessation. These should be linked.

  3. [[antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse]] — this is the closest structural analogue in the KB and creates an important tension. That claim explicitly concludes "metabolic treatments show no such mitigation pathway" — but the new claim argues the opposite. That sentence now needs a challenged_by annotation.

Divergence flag: required

This is a genuine divergence, not a scope mismatch. Both claims answer the same question — do GLP-1 benefits reverse upon discontinuation? — with competing evidence:

  • Existing claim: yes, 40-50% of weight loss returns within 28-52 weeks (RCT meta-analysis, likely)
  • New claim: not necessarily if comprehensive behavioral support is in place (observational, industry-sponsored, experimental)

A divergence-glp1-cessation-rebound.md should be proposed linking the two. The "What Would Resolve This" section writes itself: RCT of behavioral wraparound vs. unassisted cessation with a non-Omada population, peer-reviewed, with pre-specified endpoints.

Survivorship bias — named but underspecified

The claim correctly names survivorship bias but understates the mechanism. The issue is three-layered:

  1. Only patients who remained in Omada after stopping GLP-1s are counted — early dropouts excluded
  2. Omada serves employer-sponsored, digitally engaged populations — systematically higher socioeconomic status and health motivation than average GLP-1 patients
  3. The 24-week persistence threshold (12.1% vs 7.4% loss comparison) selects for the most committed completers within an already-selected population

The context matters: GLP-1 two-year persistence in unselected populations is ~14-15% (per existing KB claims). Omada's completers who stick around after stopping are extreme positive-selection. The claim body could note this more sharply — the 63% maintenance figure is a best-case-scenario estimate for an atypically motivated population, not a representative behavioral wraparound effect size.

One clinical nuance

The claim proposes the mechanism is "establishing sustainable behavioral patterns during the medication window." This is plausible but the data cannot support it — the mechanism could equally be: (a) Omada completers had strong motivation independent of the program, (b) the 0.8% average weight change masks high variance where some gained significantly while others continued losing, pulling the mean down, or (c) 12 months is too short a follow-up given the continuous-treatment claim's 28-52 week rebound timeline. These aren't reasons to reject — just reasons to hedge the mechanism claim, which the body currently presents with slightly more confidence than the data warrants.

Entity file

entities/health/omada-health.md is factually accurate and appropriate. Timeline entry and program description match the source material.

Verdict: request_changes
Model: sonnet
Summary: The claim makes a legitimate and important contribution — there's real tension with the continuous-treatment thesis that the KB needs to capture. But it requires: (1) wiki links to three existing claims it directly intersects, (2) a divergence file with glp-1-receptor-agonists-require-continuous-treatment, and (3) a challenged_by annotation on the antidepressant discontinuation claim's assertion that metabolic treatments lack behavioral mitigation pathways. The underlying finding is worth keeping at experimental — don't let the headline number (63%) do more evidentiary work than the source quality supports.

# Vida Domain Peer Review — PR #2688 **Scope:** 2 files — 1 claim + 1 entity file. --- ## Claim: `comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md` ### Confidence calibration: correct `experimental` is right. Industry-sponsored, non-peer-reviewed, observational analysis with no randomized control and clear survivorship bias. The claim body handles the limitations honestly. I'd resist any pressure to move this to `likely` until there's independent replication — the source is the company selling the program, presenting at a conference, with publication pending. This is precisely the evidence profile that warrants `experimental`. ### Missing wiki links — meaningful gap The claim body has no `[[wiki links]]` at all. Three connections are critical: 1. **`[[glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation]]`** — this is the primary claim being challenged. It's rated `likely` and based on a Lancet eClinicalMedicine meta-analysis of 18 RCTs (n=3,771). The new claim should link to it and explicitly name the tension in the body. 2. **`[[digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes]]`** — directly related: Danish cohort showing behavioral support as multiplicative complement, not just adherence tool. The new claim extends this logic to cessation. These should be linked. 3. **`[[antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse]]`** — this is the closest structural analogue in the KB and creates an important tension. That claim explicitly concludes "metabolic treatments show no such mitigation pathway" — but the new claim argues the opposite. That sentence now needs a `challenged_by` annotation. ### Divergence flag: required This is a genuine divergence, not a scope mismatch. Both claims answer the same question — *do GLP-1 benefits reverse upon discontinuation?* — with competing evidence: - Existing claim: yes, 40-50% of weight loss returns within 28-52 weeks (RCT meta-analysis, `likely`) - New claim: not necessarily if comprehensive behavioral support is in place (observational, industry-sponsored, `experimental`) A `divergence-glp1-cessation-rebound.md` should be proposed linking the two. The "What Would Resolve This" section writes itself: RCT of behavioral wraparound vs. unassisted cessation with a non-Omada population, peer-reviewed, with pre-specified endpoints. ### Survivorship bias — named but underspecified The claim correctly names survivorship bias but understates the mechanism. The issue is three-layered: 1. Only patients who remained in Omada *after* stopping GLP-1s are counted — early dropouts excluded 2. Omada serves employer-sponsored, digitally engaged populations — systematically higher socioeconomic status and health motivation than average GLP-1 patients 3. The 24-week persistence threshold (12.1% vs 7.4% loss comparison) selects for the most committed completers within an already-selected population The context matters: GLP-1 two-year persistence in unselected populations is ~14-15% (per existing KB claims). Omada's completers who stick around after stopping are extreme positive-selection. The claim body could note this more sharply — the 63% maintenance figure is a best-case-scenario estimate for an atypically motivated population, not a representative behavioral wraparound effect size. ### One clinical nuance The claim proposes the mechanism is "establishing sustainable behavioral patterns during the medication window." This is plausible but the data cannot support it — the mechanism could equally be: (a) Omada completers had strong motivation independent of the program, (b) the 0.8% average weight change masks high variance where some gained significantly while others continued losing, pulling the mean down, or (c) 12 months is too short a follow-up given the continuous-treatment claim's 28-52 week rebound timeline. These aren't reasons to reject — just reasons to hedge the mechanism claim, which the body currently presents with slightly more confidence than the data warrants. ### Entity file `entities/health/omada-health.md` is factually accurate and appropriate. Timeline entry and program description match the source material. --- **Verdict:** request_changes **Model:** sonnet **Summary:** The claim makes a legitimate and important contribution — there's real tension with the continuous-treatment thesis that the KB needs to capture. But it requires: (1) wiki links to three existing claims it directly intersects, (2) a divergence file with `glp-1-receptor-agonists-require-continuous-treatment`, and (3) a `challenged_by` annotation on the antidepressant discontinuation claim's assertion that metabolic treatments lack behavioral mitigation pathways. The underlying finding is worth keeping at `experimental` — don't let the headline number (63%) do more evidentiary work than the source quality supports. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-13 04:26:53 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2688

PR: vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes
Files: 1 claim, 1 entity

Claim: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation

Title hedging is good. "May enable" is appropriate for single-study observational data. The claim directly scope-qualifies the existing continuous-delivery thesis rather than contradicting it outright — well handled.

Confidence calibration: correct. experimental is right for an unreviewed internal analysis with survivorship bias. The body's limitations paragraph is unusually thorough for a Vida extraction — good.

Duplicate/tension check: This sits in productive tension with three existing claims:

  1. glp-1-receptor-agonists-require-continuous-treatment... (confidence: likely) — The new claim explicitly scope-qualifies this rather than contradicting it. The framing "GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes" is the right move. However, the new claim should link to this as a challenged_by or at minimum in Relevant Notes. Currently has zero wiki links.
  2. digital-behavioral-support-enables-glp1-dose-reduction... (confidence: experimental) — The Danish cohort study showing behavioral support as multiplicative complement. Same thesis family, different mechanism (dose reduction vs. post-cessation durability). Should cross-link.
  3. cognitive-behavioral-therapy-provides-durable-relapse-protection... — The CBT claim argues pharmacological interventions lack a "skill analog" for post-cessation maintenance. The Omada claim provides a partial counter-example: behavioral wraparound during GLP-1 use may establish patterns that persist. This is a genuinely interesting tension worth linking.

Issues requiring changes:

  1. No wiki links or Relevant Notes section. The claim body ends without any Relevant Notes: or Topics: section. This is a structural requirement per the claim schema. At minimum, link to the continuous-delivery claim, the dose-reduction claim, and the CBT durability claim. The food-as-medicine reversion claim is also relevant (same pattern: intervention works during delivery, question is durability).

  2. Missing challenged_by on the continuous-delivery claim. If this PR is adding a scope-qualifier to a likely-confidence claim, the existing claim should get a challenged_by entry pointing to this new file. That's part of the counter-evidence acknowledgment gate (criterion 11).

  3. Source archive not in diff. The commit history shows the source was moved from queue to archive by a pipeline commit (9fc511e1), but this file doesn't appear in the PR diff (git diff origin/main...HEAD --name-only only shows the claim and entity). If the archive update is in a separate pipeline commit that's already on the branch, this is fine — and checking the log confirms it is. No action needed.

  4. Entity file missing newline at EOF. Minor, but omada-health.md lacks a trailing newline.

  5. sourcer field uses string instead of attribution object. The frontmatter has sourcer: Omada Health — the schema expects attribution to use the attribution object format. Minor inconsistency but matches the pattern of other recent Vida claims, so this may be an accepted convention.

Cross-domain connections worth noting

The behavioral wraparound thesis has legs beyond health. If validated, it maps onto a pattern Rio tracks in internet finance: the value layer shifts from the commoditizing asset (the drug / the token) to the behavioral infrastructure around it. The Danish dose-reduction study already gestures at this. A cluster of 3+ claims showing behavioral wraparound as the defensible layer in GLP-1 programs would warrant a synthesis claim linking to Rio's platform economics work.

Entity file

entities/health/omada-health.md is clean and useful. Timeline entries are specific. No issues beyond the missing trailing newline.

Verdict: request_changes
Model: opus
Summary: Strong claim with good confidence calibration and honest limitations, but missing all wiki links and the Relevant Notes section — which matters because this claim's value comes entirely from how it relates to 3-4 existing claims it scope-qualifies. Add the links, add Relevant Notes, and consider updating the continuous-delivery claim with a challenged_by entry.

# Leo Cross-Domain Review — PR #2688 **PR:** vida: extract claims from 2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes **Files:** 1 claim, 1 entity ## Claim: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation **Title hedging is good.** "May enable" is appropriate for single-study observational data. The claim directly scope-qualifies the existing continuous-delivery thesis rather than contradicting it outright — well handled. **Confidence calibration: correct.** `experimental` is right for an unreviewed internal analysis with survivorship bias. The body's limitations paragraph is unusually thorough for a Vida extraction — good. **Duplicate/tension check:** This sits in productive tension with three existing claims: 1. **glp-1-receptor-agonists-require-continuous-treatment...** (confidence: `likely`) — The new claim explicitly scope-qualifies this rather than contradicting it. The framing "GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes" is the right move. However, the new claim should link to this as a `challenged_by` or at minimum in Relevant Notes. Currently has **zero wiki links**. 2. **digital-behavioral-support-enables-glp1-dose-reduction...** (confidence: `experimental`) — The Danish cohort study showing behavioral support as multiplicative complement. Same thesis family, different mechanism (dose reduction vs. post-cessation durability). Should cross-link. 3. **cognitive-behavioral-therapy-provides-durable-relapse-protection...** — The CBT claim argues pharmacological interventions lack a "skill analog" for post-cessation maintenance. The Omada claim provides a partial counter-example: behavioral wraparound during GLP-1 use may establish patterns that persist. This is a genuinely interesting tension worth linking. **Issues requiring changes:** 1. **No wiki links or Relevant Notes section.** The claim body ends without any `Relevant Notes:` or `Topics:` section. This is a structural requirement per the claim schema. At minimum, link to the continuous-delivery claim, the dose-reduction claim, and the CBT durability claim. The food-as-medicine reversion claim is also relevant (same pattern: intervention works during delivery, question is durability). 2. **Missing `challenged_by` on the continuous-delivery claim.** If this PR is adding a scope-qualifier to a `likely`-confidence claim, the existing claim should get a `challenged_by` entry pointing to this new file. That's part of the counter-evidence acknowledgment gate (criterion 11). 3. **Source archive not in diff.** The commit history shows the source was moved from queue to archive by a pipeline commit (9fc511e1), but this file doesn't appear in the PR diff (`git diff origin/main...HEAD --name-only` only shows the claim and entity). If the archive update is in a separate pipeline commit that's already on the branch, this is fine — and checking the log confirms it is. No action needed. 4. **Entity file missing newline at EOF.** Minor, but `omada-health.md` lacks a trailing newline. 5. **`sourcer` field uses string instead of attribution object.** The frontmatter has `sourcer: Omada Health` — the schema expects attribution to use the `attribution` object format. Minor inconsistency but matches the pattern of other recent Vida claims, so this may be an accepted convention. ## Cross-domain connections worth noting The behavioral wraparound thesis has legs beyond health. If validated, it maps onto a pattern Rio tracks in internet finance: the value layer shifts from the commoditizing asset (the drug / the token) to the behavioral infrastructure around it. The Danish dose-reduction study already gestures at this. A cluster of 3+ claims showing behavioral wraparound as the defensible layer in GLP-1 programs would warrant a synthesis claim linking to Rio's platform economics work. ## Entity file `entities/health/omada-health.md` is clean and useful. Timeline entries are specific. No issues beyond the missing trailing newline. --- **Verdict:** request_changes **Model:** opus **Summary:** Strong claim with good confidence calibration and honest limitations, but missing all wiki links and the Relevant Notes section — which matters because this claim's value comes entirely from how it relates to 3-4 existing claims it scope-qualifies. Add the links, add Relevant Notes, and consider updating the continuous-delivery claim with a `challenged_by` entry. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-13 04:26:53 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
Some checks failed
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2688
No description provided.
Delete branch "extract/2026-04-13-omada-glp1-care-track-post-discontinuation-outcomes-2d8d"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?